Serving on Novozymes' Board of Directors since 2007, Mathias Uhlén will not seek for re-election as part of the succession plan of the Board of Directors. Through his 15 years on the Board, Mathias has contributed significantly through his deep understanding of research and development, biotechnology, intellectual property rights and innovation pipeline management.